Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company focused on
acquiring, developing and commercializing diagnostic tests and risk assessment
technologies for unmet clinical needs, is pleased to provide the market with an
update on a series of rolling PreVu(R) POC Skin Cholesterol Testing Clinics that
are scheduled to be held across Canada throughout March and April and into the
spring.  


"Over 80 pharmacies under the London Drugs banner in Western Canada and the
PharmaChoice banner in Eastern Canada, are currently preparing to launch PreVu
POC Testing Clinics, in every province except Quebec, this coming March and
April," said Paul Moreau, Vice President, Sales and Marketing for Miraculins
Inc. "The London Drugs Clinics represent the second stage of PreVu POC Testing
expansion plans through the pharmacy's chain and the PharmaChoice Clinics
represent the leading edge of network expansion into PharmaChoice pharmacies in
Eastern Canada. Expansion news related to the Quebec pharmacy segment is
anticipated at the conclusion of sales and marketing discussions with interested
parties currently underway."  


"The commencement of these extensive PreVu POC Testing Clinics will also mark
the continuation of an expansive public relations campaign by Miraculins to
further raise marketplace awareness about the test and its benefits. In
addition, specially developed educational programming is being made available to
help educate healthcare professionals, general practitioners and lipid
specialists about the science behind PreVu and the technology's clinical utility
and application," added Moreau.   


A complete list of the London Drugs and PharmaChoice PreVu POC Testing locations
featuring clinics in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario,
Nova Scotia, New Brunswick, Prince Edward Island, and Newfoundland for this
March and April can be accessed at http://www.prevu.com/PreVu_Clinics.pdf.
Additional locations will continue to be added in both Eastern and Western
Canada in the months that follow, with the expectation that participating stores
will transition to offering PreVu POC testing as an ongoing risk assessment
service available either through walk-up request or by appointment, as well as
through ongoing rotating clinics.


About the PreVu Non-Invasive Skin Cholesterol Test 

The PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test is a
non-invasive, risk assessment technology designed to measure skin cholesterol -
an important new biomarker in assessing risk of coronary artery disease ("CAD").
The PreVu(R) POC Test is completely painless, non-invasive, involves no blood
draw or needles, and requires no overnight fasting. This in vitro diagnostic
test is conducted on the palm of the hand in less than 5 minutes with results
being immediately available, facilitating point of care consultation and a next
steps discussion. Skin cholesterol is the cholesterol that has been deposited
and diffused into tissue, as opposed to freely circulating in the bloodstream,
and the skin contains approximately 11% of all the cholesterol found in the
human body, by weight. Elevated skin cholesterol has been shown in clinical
studies to be strongly associated with significant CAD as measured by treadmill
stress testing and coronary angiography, as well as measured by testing for
coronary calcium, carotid artery thickening, and carotid artery plaque. The
PreVu POC Test does not diagnose the presence or absence of CAD, but helps to
identify patients who may be at higher, hidden risk for CAD by measuring this
new biomarker. For more information, visit www.prevu.com.


About Miraculins Inc. 

Miraculins is a medical diagnostic company focused on acquiring, developing and
commercializing non-invasive tests for unmet clinical needs. A significant
number of promising diagnostic opportunities remain un-commercialized because of
the sizable gap between the discovery stage, when research institutions are
typically involved, and the commercialization stage, when the larger commercial
enterprises become interested. Miraculins has direct experience in bridging this
gap. The Company's PreVu(R) technology is a revolutionary new coronary artery
disease risk assessment technology that measures cholesterol levels in a
patient's skin non-invasively, painlessly and without the need for fasting.
Miraculins is also advancing a suite of biomarkers to aid in the early detection
of the devastating disease of pregnancy known as preeclampsia. The Company's
preeclampsia program is partnered with Alere Inc., one of the world's largest
diagnostic companies. For more information, visit www.miraculins.com.


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, including,
without limitation, our anticipated future operating results, and can, in some
cases, be identified by the use of words such as "believe", "anticipate",
"expect", "intend", "plan", "will", "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements. 


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: Miraculins' early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in Miraculins' filings with Canadian securities regulatory
authorities, as well as Miraculins' ability to anticipate and manage the risks
associated with the foregoing. Additional information about these factors and
about the material factors or assumptions underlying such forward-looking
statements may be found in the body of this news release. Miraculins cautions
that the foregoing list of important factors that may affect future results is
not exhaustive. When relying on Miraculins' forward-looking statements to make
decisions with respect to Miraculins investors and others should carefully
consider the foregoing factors and other uncertainties and potential events. 


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, Miraculins
cannot provide assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to update or
revise any forward-looking statement. 


PreVu(R) is a registered trademark of Miraculins Inc. All Rights Reserved. 2013.

FOR FURTHER INFORMATION PLEASE CONTACT: 
Miraculins Inc.
Paul J. Moreau
Vice President, Sales & Marketing
204-478-5603
204-453-1546 (FAX)


Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1596 (FAX)
info@miraculins.com
www.miraculins.com
Colonial Coal (TSXV:CAD)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Colonial Coal Charts.
Colonial Coal (TSXV:CAD)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Colonial Coal Charts.